{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T18:18:20Z","timestamp":1791310700026,"version":"4.3.1"},"reference-count":44,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"20","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2009,7,10]]},"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p> This is a multicenter phase I\/II dose-finding study in relapsed\/refractory B-cell non-Hodgkin's lymphoma (NHL) evaluating veltuzumab, a humanized anti-CD20 antibody with structure-function differences from chimeric rituximab. <\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and Methods<\/jats:title><jats:p> Eighty-two patients (median age, 64 years; 79% stage III\/IV, one to nine prior treatments) received four once-weekly doses of 80 to 750 mg\/m<jats:sup>2<\/jats:sup> of veltuzumab and were assessed for safety, efficacy, pharmacodynamics, pharmacokinetics, and immunogenicity. <\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p> Veltuzumab was well tolerated, with no grade 3 to 4 drug-related adverse events despite short infusion times (typically 2 hours initially, 1 hour subsequently at doses &lt; 375 mg\/m<jats:sup>2<\/jats:sup>). In follicular lymphoma, 24 (44%) of 55 patients had objective responses (OR), with 15 (27%) complete responses (CRs) or CRs unconfirmed (CRus) by International Working Group criteria, and with some responses occurring despite two to five prior rituximab-containing regimens, less favorable prognosis (elevated lactate dehydrogenase, tumors &gt; 5 cm, and Follicular Lymphoma International Prognostic Index \u2265 2), and at all dose levels. The CRs\/CRus were durable (median duration, 19.7 months), with five patients still ongoing (15.9 to 37.6 months duration). In marginal zone lymphoma, five (83%) of six patients had ORs, with two CRs\/CRus (33%), and in diffuse large B-cell lymphoma, three (43%) of seven patients achieved partial responses. At all dose levels studied, B cells were depleted after the first infusion, veltuzumab serum half-lives were similar after the fourth infusion, and mean antibody serum levels exceeded values considered important for anti-CD20 therapy (ie, 25 \u03bcg\/mL). <\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p> Veltuzumab appeared safe and active at all tested doses, encouraging further study, including dose levels less than those typically used with rituximab. <\/jats:p><\/jats:sec>","DOI":"10.1200\/jco.2008.19.9117","type":"journal-article","created":{"date-parts":[[2009,5,19]],"date-time":"2009-05-19T01:47:03Z","timestamp":1242697623000},"page":"3346-3353","source":"Crossref","is-referenced-by-count":139,"title":["Humanized Anti-CD20 Antibody, Veltuzumab, in Refractory\/Recurrent Non-Hodgkin's Lymphoma: Phase I\/II Results"],"prefix":"10.1200","volume":"27","author":[{"given":"Franck","family":"Morschhauser","sequence":"first","affiliation":[{"name":"From the Service des Maladies du Sang Centre Hospitalier Regional, Lille; Centre Hospitalier Lyon-Sud, Lyon, France; New York Presbyterian Hospital, Weill Cornell Medical College, New York, NY; The University of Texas M. D. Anderson Cancer Center, Houston, TX; Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA; Medical Research Council Toxicology Unit, Leicester University, Leicester, United Kingdom; Immunomedics, Inc, Morris Plains; and Garden State Cancer Center, Belleville, NJ."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Leonard","sequence":"additional","affiliation":[{"name":"From the Service des Maladies du Sang Centre Hospitalier Regional, Lille; Centre Hospitalier Lyon-Sud, Lyon, France; New York Presbyterian Hospital, Weill Cornell Medical College, New York, NY; The University of Texas M. D. Anderson Cancer Center, Houston, TX; Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA; Medical Research Council Toxicology Unit, Leicester University, Leicester, United Kingdom; Immunomedics, Inc, Morris Plains; and Garden State Cancer Center, Belleville, NJ."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Fayad","sequence":"additional","affiliation":[{"name":"From the Service des Maladies du Sang Centre Hospitalier Regional, Lille; Centre Hospitalier Lyon-Sud, Lyon, France; New York Presbyterian Hospital, Weill Cornell Medical College, New York, NY; The University of Texas M. D. Anderson Cancer Center, Houston, TX; Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA; Medical Research Council Toxicology Unit, Leicester University, Leicester, United Kingdom; Immunomedics, Inc, Morris Plains; and Garden State Cancer Center, Belleville, NJ."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Coiffier","sequence":"additional","affiliation":[{"name":"From the Service des Maladies du Sang Centre Hospitalier Regional, Lille; Centre Hospitalier Lyon-Sud, Lyon, France; New York Presbyterian Hospital, Weill Cornell Medical College, New York, NY; The University of Texas M. D. Anderson Cancer Center, Houston, TX; Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA; Medical Research Council Toxicology Unit, Leicester University, Leicester, United Kingdom; Immunomedics, Inc, Morris Plains; and Garden State Cancer Center, Belleville, NJ."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Odile","family":"Petillon","sequence":"additional","affiliation":[{"name":"From the Service des Maladies du Sang Centre Hospitalier Regional, Lille; Centre Hospitalier Lyon-Sud, Lyon, France; New York Presbyterian Hospital, Weill Cornell Medical College, New York, NY; The University of Texas M. D. Anderson Cancer Center, Houston, TX; Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA; Medical Research Council Toxicology Unit, Leicester University, Leicester, United Kingdom; Immunomedics, Inc, Morris Plains; and Garden State Cancer Center, Belleville, NJ."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morton","family":"Coleman","sequence":"additional","affiliation":[{"name":"From the Service des Maladies du Sang Centre Hospitalier Regional, Lille; Centre Hospitalier Lyon-Sud, Lyon, France; New York Presbyterian Hospital, Weill Cornell Medical College, New York, NY; The University of Texas M. D. Anderson Cancer Center, Houston, TX; Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA; Medical Research Council Toxicology Unit, Leicester University, Leicester, United Kingdom; Immunomedics, Inc, Morris Plains; and Garden State Cancer Center, Belleville, NJ."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Schuster","sequence":"additional","affiliation":[{"name":"From the Service des Maladies du Sang Centre Hospitalier Regional, Lille; Centre Hospitalier Lyon-Sud, Lyon, France; New York Presbyterian Hospital, Weill Cornell Medical College, New York, NY; The University of Texas M. D. Anderson Cancer Center, Houston, TX; Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA; Medical Research Council Toxicology Unit, Leicester University, Leicester, United Kingdom; Immunomedics, Inc, Morris Plains; and Garden State Cancer Center, Belleville, NJ."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin J.S.","family":"Dyer","sequence":"additional","affiliation":[{"name":"From the Service des Maladies du Sang Centre Hospitalier Regional, Lille; Centre Hospitalier Lyon-Sud, Lyon, France; New York Presbyterian Hospital, Weill Cornell Medical College, New York, NY; The University of Texas M. D. Anderson Cancer Center, Houston, TX; Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA; Medical Research Council Toxicology Unit, Leicester University, Leicester, United Kingdom; Immunomedics, Inc, Morris Plains; and Garden State Cancer Center, Belleville, NJ."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Horne","sequence":"additional","affiliation":[{"name":"From the Service des Maladies du Sang Centre Hospitalier Regional, Lille; Centre Hospitalier Lyon-Sud, Lyon, France; New York Presbyterian Hospital, Weill Cornell Medical College, New York, NY; The University of Texas M. D. Anderson Cancer Center, Houston, TX; Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA; Medical Research Council Toxicology Unit, Leicester University, Leicester, United Kingdom; Immunomedics, Inc, Morris Plains; and Garden State Cancer Center, Belleville, NJ."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Teoh","sequence":"additional","affiliation":[{"name":"From the Service des Maladies du Sang Centre Hospitalier Regional, Lille; Centre Hospitalier Lyon-Sud, Lyon, France; New York Presbyterian Hospital, Weill Cornell Medical College, New York, NY; The University of Texas M. D. Anderson Cancer Center, Houston, TX; Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA; Medical Research Council Toxicology Unit, Leicester University, Leicester, United Kingdom; Immunomedics, Inc, Morris Plains; and Garden State Cancer Center, Belleville, NJ."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William A.","family":"Wegener","sequence":"additional","affiliation":[{"name":"From the Service des Maladies du Sang Centre Hospitalier Regional, Lille; Centre Hospitalier Lyon-Sud, Lyon, France; New York Presbyterian Hospital, Weill Cornell Medical College, New York, NY; The University of Texas M. D. Anderson Cancer Center, Houston, TX; Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA; Medical Research Council Toxicology Unit, Leicester University, Leicester, United Kingdom; Immunomedics, Inc, Morris Plains; and Garden State Cancer Center, Belleville, NJ."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Goldenberg","sequence":"additional","affiliation":[{"name":"From the Service des Maladies du Sang Centre Hospitalier Regional, Lille; Centre Hospitalier Lyon-Sud, Lyon, France; New York Presbyterian Hospital, Weill Cornell Medical College, New York, NY; The University of Texas M. D. Anderson Cancer Center, Houston, TX; Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA; Medical Research Council Toxicology Unit, Leicester University, Leicester, United Kingdom; Immunomedics, Inc, Morris Plains; and Garden State Cancer Center, Belleville, NJ."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.8.2825"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1517\/14796694.1.3.297"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2006.00789.x"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2006.10.005"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.04.020"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011795"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.1003"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-08-3175"},{"key":"B9","first-page":"556a","volume":"23","author":"Hochster HS","year":"2004","journal-title":"Proc Am Soc Clin Oncol"},{"key":"B10","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","volume":"106","author":"Hiddemann W","year":"2005","journal-title":"Blood"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1191\/0961203305lu2138oa"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.2741\/2222"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/art.22025"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0706383"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0b013e3282f5e08d"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2008.02.007"},{"key":"B17","first-page":"S66","volume":"54","author":"Genovese MC","year":"2006","journal-title":"Arthritis Rheum"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V110.11.645.645"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-117671"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-09-111781"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-03-0493"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-07-168146"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keh533"},{"key":"B24","doi-asserted-by":"crossref","first-page":"683a","DOI":"10.1182\/blood.V106.11.683.683","volume":"106","author":"Morschhauser F","year":"2005","journal-title":"Blood"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V108.11.2719.2719"},{"key":"B26","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1200\/JCO.2006.09.2346","volume":"25","author":"Morschhauser F","year":"2007","journal-title":"Proc Am Soc Clin Oncol"},{"key":"B27","first-page":"691","volume-title":"Neoplastic Hematopathology","author":"Harris NL","year":"2001","edition":"2"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-12-4434"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199309303291402"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.17.3135"},{"key":"B33","first-page":"1927","volume":"92","author":"Coiffier B","year":"1998","journal-title":"Blood"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdf155"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.2.317"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1080\/10428190410001714043"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008416911099"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.12.171"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2006.09.004"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V84.8.2457.2457"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.10.3266"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2007.06.151"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.172.5.3280"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.177.10.7435"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-01-0159"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2008.19.9117","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,26]],"date-time":"2022-05-26T00:12:54Z","timestamp":1653523974000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2008.19.9117"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,7,10]]},"references-count":44,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2009,7,10]]}},"alternative-id":["10.1200\/JCO.2008.19.9117"],"URL":"https:\/\/doi.org\/10.1200\/jco.2008.19.9117","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,7,10]]}}}